Figure 1:
Figure 2:
Breakdown of cervical lymph node involvement (n=88)
| Positive cervical lymph node (involvement by levels) | Number of subjects (percentage) |
|---|---|
| No lymph node involved | 66 (75.0) |
| Ipsilateral positive level I | 11 (12.5) |
| Ipsilateral positive levels I and II | 2 (2.3) |
| Ipsilateral positive level I and III | 1 (1.1) |
| Bilateral positive level I | 1 (1.1) |
| Ipsilateral positive level II | 7 (8.0) |
Details of subjects with primary local recurrence (n=26)
| Total patients with recurrence | Number of patients (percentage) |
|---|---|
| Involved margins | 7 (26.9) |
| Close margins | 5 (19.2) |
| Level I positive lymph node | 5 (19.2) |
| Involved/close margins and level I positive lymph node | 5 (19.2) |
| Clear margins and level I (pN0) | 4 (15.3) |
Characteristics of demographics and clinical data (n=88)
| Variable | Number of sub-jects (percentage) |
|---|---|
| Gender | |
| Male | 71 (80.68) |
| Female | 17 (19.31) |
| Median age | 55.3 (25–79) years |
| Mean follow-up months | 33.5 (4–75) months |
| Risk factors: (Smoking, chewable tobacco, betel nut, alcohol) | |
| Yes | 59 (67.04) |
| No | 29 (32.95) |
| Primary site | |
| Buccal mucosa | 37 (42.05) |
| Tongue | 24 (27.27) |
| Lower alveolus | 27 (30.68) |
| pTNM stage: | |
| No primary tumor (salvage surgery post-induction chemotherapy) | 3 (3.40) |
| Stage I | 14 (15.90) |
| Stage II | 27 (30.68) |
| Stage III | 18 (20.45) |
| Stage IV | 26 (29.54) |
| Flap complications | |
| Complete loss | 3 (3.40) |
| Partial loss/salvaged | 17 (19.31) |
| Uneventful recovery | 68 (77.27) |
Summary of pattern of recurrence (n=88)
| Recurrence | Number of subjects (percentage) |
|---|---|
| No recurrence | 51 (58.0) |
| Local recurrence | 10 (11.4) |
| Local recurrence away from flap | 10 (11.4) |
| Local and nodal recurrence | 6 (6.8) |
| Nodal recurrence | 9 (10.2) |
| Distant metastasis | 1 (1.1) |
| Lost to follow-up | 1 (1.1) |